Chikungunya Virus Infection Clinical Trial
— YOCHIKOfficial title:
Impact of Yoga on Quality of Life in Patients With Chronic Chikungunya: A Randomized Controlled Study
Verified date | July 2020 |
Source | Centre Hospitalier Universitaire de Pointe-a-Pitre |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the benefits of a 8-week yoga program on quality of
life in patients suffering from chronic chikungunya.
Studies have already shown the effectiveness of yoga practice on various arthralgia's, on the
reduction of inflammatory reactions, on psychological disorders/sleep disorders and on
quality of life. Considering quality of life as a global experience of balance between
physical and mental wellbeing, the hypothesis was that the practice of yoga would globally
improve the quality of life of patients with chronic chikungunya.
Status | Terminated |
Enrollment | 42 |
Est. completion date | March 30, 2020 |
Est. primary completion date | March 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Patients suffering from chronic chikungunya, as documented by a positive chikungunya serology and the following symptoms: polyarthralgia and/or musculoskeletal disorder and/or morning stiffness. - Patients had to be between 18 and 70 years old, and be - patients affiliated to the French social insurance. Exclusion Criteria: - being pregnant; - suffering from pre-existing rheumatic diseases before the Chikungunya infection; - showing acute symptoms of a Chikungunya infection (documented serology); - being unable to practice yoga poses ; having been recently treated with methotrexate or corticosteroids (less than 3 months ago); - being under guardianship, trusteeship or legal protection, - participating in another research study, - showing severely impaired physical and/or psychological health, which in the opinion of the investigator, may affect the compliance of the study participant. |
Country | Name | City | State |
---|---|---|---|
Guadeloupe | Mouffias' Medical Center in Guadeloupe. | Pointe-à-Pitre |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Pointe-a-Pitre |
Guadeloupe,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Health Related Quality of Life - Short Form-36 (SF-36) | This scale measures eight health domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health) of quality of life for adults aged 18 and older. Using a scoring algorithm, the aggregated scores can provide two summary scores: the physical component summary (PCS) score and the mental component summary (MCS) score. | At baseline | |
Primary | Health Related Quality of Life - Short Form-36 (SF-36) | This scale measures eight health domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health) of quality of life for adults aged 18 and older. Using a scoring algorithm, the aggregated scores can provide two summary scores: the physical component summary (PCS) score and the mental component summary (MCS) score. | after 8 weeks of intervention | |
Primary | Health Related Quality of Life - Short Form-36 (SF-36) | This scale measures eight health domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health) of quality of life for adults aged 18 and older. Using a scoring algorithm, the aggregated scores can provide two summary scores: the physical component summary (PCS) score and the mental component summary (MCS) score. | after 18 weeks | |
Secondary | nociceptive pain - Visual Analog Scale (VAS) | The Visual Analog Scale (VAS) is a 10 cm line with anchor statements on the left (no pain) and on the right (extreme pain). The patient is asked to mark their current pain level on the line. They can also be asked to mark their maximum, minimum, and average pain. The examiner scores the VAS by measuring the distance in either centimeters (0 to 10) or millimeters (0 to 100) from the "no pain" anchor point. | At baseline | |
Secondary | nociceptive pain - Visual Analog Scale (VAS) | The Visual Analog Scale (VAS) is a 10 cm line with anchor statements on the left (no pain) and on the right (extreme pain). The patient is asked to mark their current pain level on the line. They can also be asked to mark their maximum, minimum, and average pain. The examiner scores the VAS by measuring the distance in either centimeters (0 to 10) or millimeters (0 to 100) from the "no pain" anchor point. | after 8 weeks of intervention | |
Secondary | nociceptive pain - Visual Analog Scale (VAS) | The Visual Analog Scale (VAS) is a 10 cm line with anchor statements on the left (no pain) and on the right (extreme pain). The patient is asked to mark their current pain level on the line. They can also be asked to mark their maximum, minimum, and average pain. The examiner scores the VAS by measuring the distance in either centimeters (0 to 10) or millimeters (0 to 100) from the "no pain" anchor point. | after 18 weeks | |
Secondary | neuropathic pain- DN4 scale | The total score is calculated as the sum of the 10 items and the cut-off value for the diagnosis of neuropathic pain is a total score of 4/10. | At baseline | |
Secondary | neuropathic pain- DN4 scale | The total score is calculated as the sum of the 10 items and the cut-off value for the diagnosis of neuropathic pain is a total score of 4/10. | after 8 weeks of intervention | |
Secondary | neuropathic pain- DN4 scale | The total score is calculated as the sum of the 10 items and the cut-off value for the diagnosis of neuropathic pain is a total score of 4/10. | after 18 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02230163 -
Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins
|
Phase 1/Phase 2 | |
Completed |
NCT04546724 -
Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
|
Phase 3 | |
Completed |
NCT03631719 -
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
|
||
Active, not recruiting |
NCT04441905 -
Phase 1 Study of SAR440894 vs Placebo
|
Phase 1 | |
Completed |
NCT02562482 -
Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
|
Phase 2 | |
Completed |
NCT03028441 -
Phase I Trial of Measles Vectored Chikungungya Vaccine
|
Phase 1 | |
Completed |
NCT03807843 -
Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
|
Phase 2 | |
Completed |
NCT04909411 -
Consequences of a Maternal-fetal Chikungunya Virus Infection
|
N/A | |
Completed |
NCT04786444 -
Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults
|
Phase 3 | |
Completed |
NCT02553369 -
Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection
|
N/A | |
Recruiting |
NCT06106581 -
A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years
|
Phase 2 | |
Recruiting |
NCT06007183 -
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
|
Phase 3 | |
Completed |
NCT03635086 -
Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)
|
Phase 2 | |
Completed |
NCT02861586 -
Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine
|
Phase 2 | |
Active, not recruiting |
NCT04838444 -
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)
|
Phase 3 | |
Completed |
NCT03483961 -
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
|
Phase 2 | |
Recruiting |
NCT06028841 -
A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV)
|
Phase 3 |